Kerrie Brady’s Post

In an era where scientific breakthroughs are celebrated daily, it’s perplexing to consider the immense cost behind each one. Particularly in drug discovery, where the stakes are as high as human health, the financial figures are staggering. But why? And how can emerging technologies not just cut costs but potentially save lives? First, let's demystify the expenses. The journey from a lab bench idea to a pharmacy shelf product is not just long, spanning over a decade on average, but fraught with complexities and regulatory hurdles. Each step, from initial discovery through clinical trials, is a meticulous dance of science and compliance, with a high failure rate that necessitates substantial investment. The price tag for developing a new drug can soar into the billions. Here’s the twist: While the costs are high, the potential for technology to revolutionize this process is profound. Advances in fields like artificial intelligence, bioinformatics, and genomics are not just buzzwords; they are beacons of hope. These technologies can analyze vast datasets, predict molecular behavior, and simulate trial outcomes, potentially trimming years and millions off development timelines. But why should this matter to us all? Because in the grand scheme, every dollar saved in developing a new drug can be redirected towards making it more accessible, more affordable, and available to those who need it most. The implications extend beyond balance sheets and into the very fabric of global healthcare. As we stand on the brink of a technological renaissance in drug discovery, let's not just watch but engage. For every billion saved, there's an untold value in human life and well-being. #healthcareinnovation #biotechinnovation #drugdiscovery

Biotech and Health-tech 🌟 Exploring the Future of Biotech and Health-tech: Where Innovation Meets Impact 🌟 In a world where technological advancements are revolutionizing every aspect of our lives, the biotech and health-tech sectors stand out as beacons of hope and innovation. Here’s why these fields are capturing the imagination of visionaries and investors alike: 🔬 Biotech: The Frontier of Science Innovative Therapies: From gene editing with CRISPR to personalized medicine, biotech is paving the way for groundbreaking treatments that were once the stuff of science fiction. Disease Eradication: Advances in biotechnology are driving efforts to cure previously untreatable diseases, improving quality of life on a global scale. Sustainable Solutions: Biotech innovations are not only transforming healthcare but also addressing environmental challenges through bioengineering and sustainable practices. 🏥 Health-tech: Transforming Patient Care Digital Health Revolution: Wearable devices, telemedicine, and health apps are making healthcare more accessible and personalized than ever before. AI and Big Data: The integration of AI and big data analytics in health-tech is enabling early diagnosis, predictive analytics, and efficient patient management. Improved Outcomes: Smart health solutions are enhancing patient outcomes, reducing costs, and increasing the efficiency of healthcare systems worldwide. 💡 Why It Matters Impact on Lives: These advancements directly improve patient lives, offering hope and solutions to millions. Economic Growth: The biotech and health-tech industries are significant contributors to economic growth, creating jobs and fostering innovation. Future Potential: With continuous research and development, the potential for new discoveries and improvements is limitless.

Life Sciences Past, Present and Future 2022 was labelled the year of 'business as usual', where return to formality was put through the final stages after the pandemic. For the life sciences industry, this meant developing past challenges that had arisen in the previous couple of years and re-evaluating regulations and legalities. 2023 brought the opportunity for growth for life sciences after solid foundations were re-laid in the previous year. It was a year of action where development, discovery and action were the pinnacle of driving success within the industry.  Now looking to continuing 2024, the future looks bright for the world of life sciences. Experts are predicting that AI, new technologies and research models will support exponential growth in the industry this year. A combination of increased focus on supply chain, advanced novel modalities and partnerships will come together in forming a bright future in the industry. #lifescience #ipharm

𝗦𝘄𝗶𝘁𝘇𝗲𝗿𝗹𝗮𝗻𝗱'𝘀 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗘𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺: 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗧𝗼𝘄𝗮𝗿𝗱 𝗮 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗙𝘂𝘁𝘂𝗿𝗲🏥📈 🇨🇭Switzerland is paving the way for a digital #healthcare revolution that promises to reshape the industry's landscape. With an astounding 2.5 quintillion bytes of digital data generated daily, the potential for transformation through artificial intelligence and machine learning is unprecedented. #Switzerland at the forefront of this ground-breaking journey. 🌍 🔬 In Switzerland's vibrant biopharma hubs, a dynamic synergy emerges as traditional pharmaceutical giants like Roche, Novartis, and Johnson & Johnson collaborate seamlessly with startups, capitalizing on academic prowess and a skilled workforce. 🎓 Forward-thinking programs, offered by the University of Applied Sciences and Arts Northwestern Switzerland FHNW blends medical, data science, and business acumen, equipping graduates to pioneer the fusion of data analytics and medical realms. 🤖Harnessing machine learning for extensive data processing, collaborations with medical institutions and pharmaceutical firms yield insights propelling drug discovery, decoding intricate biological processes, and advancing precision diagnostics. Ventures like AiNET, an ETH Zürich spinout, deploy AI to revolutionize immunoinformatic. 🧬🤖 🌱Switzerland's robust innovation drive is evident, offering startup incentives, grants via Innosuisse and the SNSF Swiss National Science Foundation. Accelerators, like The Digital Health Nation Innovation Booster, bolster connections with experienced biopharma professionals, propelling breakthroughs and nurturing a vibrant digital health community. 🔗 As medical data transforms into actionable insights and concepts like immune system digital twins become reality, the nation's potent blend of biopharma legacy and pioneering technologies is propelling it into a new era. Frank Kumli Valentina Francia, PhD Basel Area Business & Innovation Emile Dupont Greater Zurich Area Greater Geneva Bern area (GGBa) Lucerne Business Economic Promotion Valais Vaud Promotion

MetaSano partners with Northeastern University students for healthcare innovation! The partnership will see students from Northeastern University's esteemed AI and chemical engineering programs lending their expertise to MetaSano's pioneering projects. With their fresh perspectives and innovative ideas, we're poised to tackle some of the most pressing challenges in healthcare. From developing the Urine Protein Scan, a cutting-edge tool for non-invasive detection of protein levels in urine, to crafting an AI Model capable of analyzing skin signals indicative of kidney issues, our joint efforts with Northeastern University students are gearing up to transform the way we approach healthcare diagnostics. The Urine Protein Scan represents a breakthrough in early detection, offering a convenient and reliable method for identifying potential kidney issues before they escalate. Meanwhile, the AI Model harnesses the power of artificial intelligence to provide users with real-time insights into their kidney health, simply by capturing a photo with their smartphone. These initiatives mark an exciting leap forward in healthcare innovation, promising to make diagnostic processes more accessible, user-friendly, and effective for all. #HealthcareInnovation #Partnership #EmpoweringStudents #kidneydisease #CKD #AI #LAB #research

Please join me and Isaac Kohane MD/PhD, Chair of the Harvard University Department of Biomedical Informatics, on February 15th for a conversation addressing urgent concerns at the intersection of AI and biomedicine. We'll be chatting about biomedical AI, venture capital as a tool for advancing scientific progress, bayesian philosophies for learning, NEJM AI, and more. Register here for free (virtual and in-person options): https://bit.ly/BIESFEB2024 #healthcare #ai #artificialintelligence #generativeai Harvard Medical School Harvard Medical School Department of Biomedical Informatics

Unleashing the Power of Digitalization in Biosciences🌿🧬 In the dynamic realm of biosciences, where innovation is the heartbeat of progress, digitalization emerges as a transformative force reshaping the landscape. The convergence of biology and technology has ushered in an era of unprecedented opportunities, unlocking new frontiers in research, healthcare, and beyond. 1. Accelerating Research and Discovery 📈 Digitalization has become the catalyst for expediting research processes in biosciences. High-throughput technologies, coupled with advanced data analytics, empower researchers to analyze vast datasets, uncovering patterns and correlations that were once elusive. 2. Precision Medicine and Personalized Healthcare 💊💉 The integration of digital technologies into biosciences has revolutionized healthcare by giving rise to precision medicine. Tailoring treatment strategies based on an individual's genetic makeup, lifestyle, and environmental factors has become possible. This personalized approach maximizes treatment efficacy while minimizing side effects, marking a paradigm shift from traditional one-size-fits-all healthcare models. 3. Big Data Analytics: Unraveling Biological Complexity 📊 Biosciences deal with intricate biological systems, and comprehending their complexity requires sophisticated analytical tools. Big data analytics, fueled by digitalization, enables scientists to sift through vast datasets, identify relevant patterns, and extract meaningful insights. From understanding disease mechanisms to predicting drug responses, big data analytics is a game-changer in decoding the intricacies of life sciences. 4. Virtual Laboratories and Simulation🧪🔬🥼 Digitalization has introduced the concept of virtual laboratories and simulations, offering a risk-free environment for experimentation and learning. This not only enhances the education and training of budding scientists but also allows seasoned researchers to test hypotheses and scenarios without the constraints of physical laboratories. #5. Collaboration and Connectivity 🖇️🔗🖥️ In an interconnected world, collaboration is key to scientific progress. Digitalization facilitates seamless collaboration among researchers, institutions, and even across geographical boundaries. Cloud-based platforms, collaborative tools, and shared databases enable real-time sharing of information, fostering a global network of knowledge exchange in biosciences. 6. Drug Discovery and Development💊⚕️🩻 Digitalization has significantly streamlined the drug discovery and development process. Computational methods, machine learning algorithms, and artificial intelligence are employed to predict drug candidates, optimize formulations, and reduce the time and costs associated with bringing new drugs to market. #digitalage #digitalbusiness #digitalassetmanagement #biosciences #biology #BioGeneVersity #drhiralraval

How can we harness technological innovation to drive down the cost of drug research and treatment, thus ensuring equitable access to healthcare for those in need? Dr. Rumin Zhang, Chief Scientific Officer at the Global Health Drug Discovery Institute (GHDDI), emphasized the transformative potential of artificial intelligence (AI) during the 2nd Global Development and Health Communication Forum hosted by Tsinghua University School of Journalism and Communication. According to Dr. Zhang, AI's primary value lies in automating tasks that are inefficient, high-risk, and highly repetitive, while assisting human efforts in advanced technological and cultural innovation. “Conventional drug research methods are known for their lengthy cycles, exorbitant costs, and uncertain success rates. AI has emerged as a pivotal force that is able to optimize efficiency across the process of drug discovery, from target identification and virtual screening to drug design and clinical trials,” he noted. GHDDI, at the forefront of technological innovation for disease treatments, has developed a cutting-edge AI-driven drug research data platform. This platform has catalyzed a series of initiatives, leading to remarkable progress in improving information accessibility and promoting equity in healthcare. To learn more about GHDDI's efforts in drug research and innovation, visit our website: ghddi.org/en. #AI #drugdiscovery #drugresearch #communications

Our August submission to Integrity Research Associates' ResearchWatch titled: Unlocking Investment Potential in Healthcare: The Role and Impact of Alternative Data by Dallán R..   From the biotech boom of the 1980s to the surge of investment in the early 2000s, the healthcare sector has seen rapid growth and advancements. The rise of alternative data sources such as wearables, patient-generated data, and EHRs is now reshaping this space, providing real-time insights into patient health and treatment outcomes.   Some key takeaways from the article: * VC companies globally invested over $52 billion into therapeutic-based biotech companies from 2019-2021. * The increasing use of alternative medical data in research offers compelling medical evidence. * Claims data, R&D data, and medical device data are all pivotal sub-categories of healthcare data that can greatly influence the industry's investment patterns. * Complying with global regulations like HIPAA, GDPR, and the recent draft AI Act is crucial, especially as data privacy concerns increase.   The balance of innovation with compliance will be pivotal in harnessing the potential of AI and alternative data. As we usher in a new era of healthcare investments, staying informed and updated with the regulatory landscape is paramount.   Check out the full article for an in-depth exploration of this topic! A must-read for healthcare professionals, investors, and data enthusiasts alike. https://lnkd.in/eswCUrV7   #Healthcare #AlternativeData #AI #Pharma #Investment #DataStrategy Michael Mayhew Sanford (Sandy) Bragg

The terms multivariate and multivariable are often used interchangeably in the public health literature. However, these terms actually represent 2 very distinct types of analyses. Statistically speaking, #multivariate analysis refers to statistical models that have 2 or more dependent or outcome variables. This type of statistical model can be used to at-tempt to assess the relationship between a number of variables; one can assess independent relationships while adjusting for potential confounders. While #multivariable analysis refers to statistical models in which there are multiple in-dependent or response variables. This type refers to the modeling of data that are often derived from longitudinal studies, wherein an outcome is measured for the same individual at multiple time points (repeated measures), or the modeling of nested/clustered data, wherein there are multiple individuals in each cluster. https://osrc.network/ References: 1. Van Belle G. Biostatistics: A Methodology for the Health Sciences. Hoboken, NJ: Wiley-Interscience; 2004. 2. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med. 2003;138(8):644–650. 3. Freedland KE, Reese RL, Steinmeyer BC. Multivari-able models in biobehavioral research. Psychosom Med. 2009;71(2):205–216.